BSH 2017 | Daratumumab in the treatment of multiple myeloma
Paul Richardson, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the use of daratumumab in the treatment of multiple myeloma at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Daratumumab is the frontline in monoclonal antibody treatment in multiple myeloma. It is the first to have monotherapy activity, and has been shown to drive approximately a third of patients into good responses. Elotuzumab is another useful antibody in the treatment of multiple myeloma, targeting SLAMF7 antigens on CD319. The POLLUX study (NCT02076009) combined daratumumab, dexamethasone and lenalidomide, and the CASTOR study (NCT02136134) combined daratumumab, dexamethasone, and bortezomib, are two Phase III trials that have shown very promising results, especially in terms of progression free survival in patients with early relapse. Another interesting result of the POLLUX study is a high rate of MRD negativity, even in relapsed, refractory patients. He states that daratumumab will change the therapeutic paradigm for the disease.
